Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses his thoughts on calls for every person diagnosed with breast cancer to receive a multigene panel.
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses his thoughts on calls for every person diagnosed with breast cancer to receive a multigene panel.
Transcript
New guidelines from the American Society of Breast Surgeons called for every person diagnosed with breast cancer to receive a multigene panel. Do you agree with this?
It’s a very complicated area who should be tested for a hereditary breast cancer gene. Today, we use panels, anywhere from 25 to 50 gene panels, which look at all the common and uncommon genes that have been identified that increase susceptibility to breast cancer. Of course, number 1 and 2 of those are BRCA1 & 2. Now we know that if you look for more genes and if you expand the criteria for looking at these genes that we’re going to find more people that have the potential for hereditary breast cancer and they can be offered prophylactic options, whether that’s surgery or increased surveillance or chemo prevention.
So, I think the American Society of Breast Surgeons took a very provocative stand because right now, if you look at the guidelines, they’re very confusing, and they’re kind of arbitrary, like NCCN [National Comprehensive Cancer Institute] says any patient under 45 should be tested but only patients between 45 and 50 who have certain family history and triple-negative patients under 60, so it’s very complicated and it probably doesn’t need to be that complicated. I definitely advocate for a broader testing.
However, we have to use our clinical judgment on whether or not we should test every 80-year-old diagnosed with breast cancer with zero family history. I think we can leave that up to the doctors, but I strongly agree with expanding the indications for comprehensive genetic testing in patients with breast cancer.
Learning From Past Innovations to Advance Ventilation Use in Respiratory Conditions
May 21st 2024In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More